Cited by 235Bipolar Disorder and TreatmentSchizophrenia research and treatmentNeurotransmitter Receptor Influence on Behavior

In Vivo D2 Dopamine Receptor Density in Psychotic and Nonpsychotic Patients With Bipolar Disorder

Pearlson, Godfrey D.·1995·Archives of General Psychiatry

Abstract

BACKGROUND: A prior positron emission tomographic study from The Johns Hopkins University, Baltimore, Md, using N-methylspiperone labeled with carbon 11 reported elevated basal ganglia D2 dopamine receptor density (Bmax) values in neuroleptic-naive schizophrenic patients compared with controls. We have now extended these studies to include patients with bipolar disorder. METHODS: Patients with bipolar disorder (n = 14) either had never received neuroleptic medication or had been neuroleptic-free for more than 6 months, and they met DSM-III criteria for currently symptomatic affective disorder. Patients with bipolar disorder were compared with matched schizophrenic patients and normal controls. All received two positron emission tomographic scans, the second of which was preceded by oral administration of haloperidol lactate, to permit the calculation of D2 dopamine receptor Bmax. RESULTS: Diagnostic groups differed in Bmax by analysis of variance (P < .0001); post hoc tests showed higher Bmax values for psychotic patients with bipolar disorder and schizophrenic patients compared with normal controls and for schizophrenic patients and psychotic patients with bipolar disorder compared with nonpsychotic patients with bipolar disorder. Among patients with bipolar disorder, Bmax values correlated significantly with the severity of psychotic symptoms (r = .63) on the Present State Examination but not with the severity of nonpsychotic mood symptoms. CONCLUSIONS: We conclude that, like schizophrenic patients, patients with psychotic bipolar disorder have elevations of D2 dopamine receptor Bmax values and that such elevations in affective disorder are more closely associated with the presence of psychosis than with mood abnormality. Elevations in dopamine receptor values thus may occur in psychiatric states that are characterized by psychotic symptoms rather than being specific to schizophrenia.

Integrity signals

Registry

Crossref · 10.1001/archpsyc.1995.03950180057008

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The presence of psychosis may moderate patterns of DA receptor binding; striatal D2 receptor signaling seems greater in psychotic patients with bipolar disorder, whereas no differences in D2 availability were found between non-psychotic patients with bipolar disorder and controls.

    “There is also evidence that the presence of psychosis may moderate patterns of DA receptor binding. Specifically, striatal D2 receptor signaling seems to be greater in psychotic patients with bipolar disorder [286,287], whereas no differences in D2 availability were found between non-psychotic patients with bipolar disorder and controls [288,289].”

Cites

Flagged first, then by citations

1 of the 42 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Pearlson, G. D.
Affiliations
Johns Hopkins University (US)
Corresponding author
Pearlson, Godfrey D.
Venue
Archives of General Psychiatry
Published
1995-06-01
Volume
52
Issue
6
Pages
471
ISSN
0003-990X (ISSN-L)
OpenAlex
W2138538568
Cited by
235
References
42
Citations by year
2026: 2 · 2025: 3 · 2024: 2 · 2023: 3 · 2022: 6 · 2021: 27 · 2020: 3 · 2019: 4 · 2018: 3 · 2017: 7 · 2016: 6 · 2015: 4 · 2014: 13 · 2013: 6 · 2012: 15
FWCI
7.55
Type
journal article
Language
en
Open access
closed
Locations
  • Archives of General Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (5r01mh040391-02, 5r01mh042821-07)
  • National Institute of Mental Health (MH 42821, MH-40391, MH43775)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
bipolar disorder, psychosis, schizophrenia, basal ganglia, neuroleptic-naive patients, psychotic symptom severity, dopamine receptor binding
MeSH terms
Adult, Bipolar Disorder, Brain, Carbon Radioisotopes, Caudate Nucleus, Female, Haloperidol, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Psychotic Disorders, Putamen, Receptors, Dopamine, Schizophrenia, Spiperone, Tomography, Emission-Computed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review